1h Free Analyst Time
The global liquid biopsy market is expected to grow at a CAGR of 23.19% from 2022-2028.Speak directly to the analyst to clarify any post sales queries you may have.
MARKET TRENDS & DRIVERS
Increasing Role of Liquid Biopsy as a Companion Diagnostics
As liquid biopsy technologies continue to advance, their role as companion diagnostics is expanding rapidly. The non-invasive nature, ability to capture tumor heterogeneity and dynamics, early detection of MRD, real-time treatment response assessment, targeted therapy selection, and biomarker discovery make liquid biopsy an invaluable tool in guiding personalized treatment strategies. The integration of liquid biopsy as a companion diagnostic is transforming the field of precision medicine, leading to more effective and tailored therapeutic approaches for patients.New Product Launches
The liquid biopsy market has witnessed several notable product launches in recent years. Companies like Guardant Health, Roche, and Illumina have introduced innovative solutions to enhance liquid biopsy capabilities. These include new liquid biopsy assays with expanded gene panels, improved sensitivity, and increased accuracy. Advanced platforms and technologies, such as digital PCR and next-generation sequencing (NGS), have also been introduced to enable more comprehensive and precise analysis of circulating biomarkers. Bioinformatics tools and software have also been developed to facilitate data analysis and interpretation, enhancing the clinical utility of liquid biopsy.Higher Patient Preference for Non-invasive Diagnosis and Monitoring
The preference for non-invasive diagnosis and monitoring methods has become a significant driver for the liquid biopsy industry. Patients and healthcare providers increasingly recognize the advantages of liquid biopsy over invasive tissue biopsies, such as reduced procedural risks, minimal discomfort, and the ability to obtain multiple samples over time. Liquid biopsy's non-invasive nature also allows for easier accessibility, especially in cases where obtaining tissue biopsies may be challenging or impractical. The growing demand for non-invasive diagnostic approaches aligns with the convenience, safety, and potential for real-time monitoring offered by liquid biopsy, contributing to its expanding adoption and market growth.INSIGHTS BY PRODUCT
The kits & reagents product segment dominated the global liquid biopsy market and is projected to witness the fastest growth rate of over 23% during the forecast period. Liquid biopsy kits and reagents are tools used to detect and diagnose cancer. Liquid biopsy kits and reagents are designed to detect and analyze specific biomarkers in the blood, urine, saliva, or other bodily fluids. Different reagents may be used to identify and measure the biomarkers depending on the type of liquid sample used. Overall, liquid biopsy kits and reagents have revolutionized the field of cancer detection and diagnosis. With these tools, clinicians can now detect and diagnose cancer more accurately, quickly, and cost-effectively than ever before.Segmentation by Product
- Kits & Reagents
- Instruments & Platforms
INSIGHTS BY SAMPLE TYPE
The global liquid biopsy market by sample type segments as blood and others. The blood segment held the largest global market share. The development of liquid biopsy has revolutionized medical diagnostics and changed how we approach disease treatment. Liquid biopsy is a type of biopsy procedure involving the extraction of genetic material from a patient’s blood or other bodily fluid for disease diagnosis and prognosis. One of the most common and widely used liquid biopsy methods is the analysis of blood samples.Segmentation by Sample Type
- Blood
- Others
INSIGHTS BY APPLICATION
The global liquid biopsy market by application segments by cancer and non-cancer.The cancer segment accounted for the largest global liquid biopsy market share. Cancer is a major health concern, and its early detection is critical for successful treatment. Unfortunately, traditional invasive biopsies are often painful, expensive, and not always suitable for cancer detection. As a result, liquid biopsy has emerged as an attractive alternative, offering the potential to detect cancer earlier and with less risk. A liquid biopsy is a minimally invasive procedure that analyzes molecules in body fluids such as blood or urine to detect cancer. By analyzing cancer-specific molecules, such as circulating tumor DNA, commonly known as ctDNA, or circulating tumor cells, liquid biopsies can accurately diagnose cancer before the tumor becomes visible.Segmentation by Application
- Cancer
- Non-cancer
INSIGHTS BY BIOMARKER TYPE
The cfDNA & ctDNA biomarker type segment dominated the global liquid biopsy market, accounting for over 41% in 2022. Cell-free DNA (cfDNA) is a rapidly developing technology in liquid biopsy that has opened a new field of cancer diagnosis and patient management. It involves DNA extraction from a sample of circulating blood, which can then be analyzed for the presence of genetic mutations. These mutations are associated with cancer development and can provide a detailed picture of a patient’s disease.Segmentation by Biomarker Type
- Cell-free DNA (cfDNA) & Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs)
INSIGHTS BY TECHNOLOGY
The next-generation sequencing (NGS) technology segment dominated the global liquid biopsy market in 2022. Liquid biopsy is a revolutionary technique that has transformed the field of cancer diagnosis and treatment. Liquid biopsy has greatly advanced the study of cancer genomics using NGS. NGS is a powerful and cost-effective technology that enables the rapid sequencing of large amounts of genetic material. NGS sequences the sample's genetic material and identifies any cancer-related mutations. Through this process, researchers can detect cancer at earlier stages and determine the type and aggressiveness of the cancer. The data generated from NGS can be used to develop targeted therapies and improve patient outcomes.Segmentation by Technology
- Next-generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
INSIGHTS BY END-USER
The hospital end-user segment accounted for the largest global liquid biopsy market share. As medical technology advances, liquid biopsy in hospitals is becoming more commonplace. Liquid biopsy is a relatively new technology that utilizes a patient’s blood, urine, or other body fluids to detect cancer cells or biomarkers. This method offers an alternative to traditional tissue biopsies, which are invasive, painful, and expensive. By detecting cancer cells or markers from a simple blood or urine sample, liquid biopsy can provide non-invasive, cost-effective, and timely diagnostic information. The use of liquid biopsy in hospitals is increasing due to its versatility and convenience. It can detect various cancers, including breast, colorectal, lung, prostate, and ovarian. It can also detect cancer at earlier stages, providing earlier diagnosis and treatment. Using liquid biopsy for cancer detection is also beneficial because it can monitor real-time response to treatment, such as chemotherapy or immunotherapy.Segmentation by End-user
- Hospitals
- Diagnostic Laboratories
- Others
GEOGRAPHICAL ANALYSIS
North America dominated the global liquid biopsy market share, accounting for over 48% in 2022. The increasing demand for liquid biopsy technology in North America comes in the face of growing cancer rates across the U.S. and Canada, as well as an increased awareness of the early diagnostic benefits of this technology. Liquid biopsies can provide detailed information on the presence of the disease, its type, and its progression in the body much earlier than traditional methods and procedures.Segmentation by Geography
North America
- The U.S.
- Canada
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
APAC
- China
- Japan
- India
- South Korea
- Australia
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
COMPETITIVE LANDSCAPE
Competing in the global liquid biopsy market demands robust clinical validation and regulatory approvals. Companies that successfully navigate regulatory pathways, obtain approvals from health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and provide solid clinical evidence gain a competitive advantage. Validated assays with regulatory endorsements instill confidence in healthcare professionals and contribute to industry penetration. Continuous advancements in sequencing technologies, digital PCR, and other analytical platforms have improved the sensitivity and specificity of liquid biopsy tests. These advancements enhance the ability to detect rare mutations and monitor tumor heterogeneity.Key Company Profiles
- Agilent Technologies
- F. Hoffmann-La Roche
- Guardant Health
- Illumina
- QIAGEN
- Thermo Fisher Scientific
Other Prominent Vendors
- Agena Bioscience
- ANGLE
- Biocept
- Biodesix
- Biolidics
- Bio-Rad Laboratories
- BIOVIEW
- Caris Life Sciences
- Epigenomics
- Freenome Holdings
- Invitae Corporation
- Laboratory Corporation of America
- Lucence Health
- LungLife AI
- mdxhealth
- Menarini Silicon Biosystems
- Natera
- NeoGenomics Laboratories
- Sysmex Corporation
- TEMPUS
KEY QUESTIONS ANSWERED:
1. How big is the liquid biopsy market?2. What is the growth rate of the global liquid biopsy market?
3. Which region dominates the global liquid biopsy market share?
4. What are the significant trends in the liquid biopsy industry?
5. Who are the key players in the global liquid biopsy market?
Table of Contents
1 Research Methodology2 Research Objectives3 Research Process7 Market at a Glance
4 Scope & Coverage
5 Report Assumptions & Caveats
6 Premium Insights
8 Introduction
9 Market Opportunities & Trends
10 Market Growth Enablers
11 Market Restraints
12 Market Landscape
13 Product
14 Sample Type
15 Application
16 Biomarker Type
17 Technology
18 End-user
19 Geography
20 North America
21 Europe
22 APAC
23 Latin America
24 Middle East & Africa
25 Competitive Landscape
26 Key Company Profiles
27 Other Prominent Vendors
28 Report Summary
29 Quantitative Summary
30 Appendix
List of Exhibits
List of Tables
Companies Mentioned
- Agilent Technologies
- F. Hoffmann-La Roche
- Guardant Health
- Illumina
- QIAGEN
- Thermo Fisher Scientific
- Agena Bioscience
- ANGLE
- Biocept
- Biodesix
- Biolidics
- Bio-Rad Laboratories
- BIOVIEW
- Caris Life Sciences
- Epigenomics
- Freenome Holdings
- Invitae Corporation
- Laboratory Corporation of America
- Lucence Health
- LungLife AI
- mdxhealth
- Menarini Silicon Biosystems
- Natera
- NeoGenomics Laboratories
- Sysmex Corporation
- TEMPUS
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 377 |
| Published | October 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 3.48 Billion |
| Forecasted Market Value ( USD | $ 12.16 Billion |
| Compound Annual Growth Rate | 23.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
